Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 385 to 388 of 388 entries
Sorted by: Best Match Show Resources per page
Reliability of televisits for patients with mild relapsing-remitting multiple sclerosis in the COVID-19 era.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology

Toscano S, Patti F, Chisari CG, Arena S, Finocchiaro C, Schillaci CE, Zappia M.
PMID: 35018548
Neurol Sci. 2022 Jan 11; doi: 10.1007/s10072-022-05868-5. Epub 2022 Jan 11.

BACKGROUND: Evidence of the cost-effectiveness of telemedicine (TM) for the management of Multiple Sclerosis (MS) has been provided recently. However, some doubts persist about the accuracy of neurological examinations performed remotely.OBJECTIVES: This study investigated the reliability of neurological evaluations...

Cite
Toscano S, Patti F, Chisari CG, et al. Reliability of televisits for patients with mild relapsing-remitting multiple sclerosis in the COVID-19 era. Neurol Sci. 2022;doi: 10.1007/s10072-022-05868-5.
Toscano, S., Patti, F., Chisari, C. G., Arena, S., Finocchiaro, C., Schillaci, C. E., & Zappia, M. (2022). Reliability of televisits for patients with mild relapsing-remitting multiple sclerosis in the COVID-19 era. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, . https://doi.org/10.1007/s10072-022-05868-5
Toscano, Simona, et al. "Reliability of televisits for patients with mild relapsing-remitting multiple sclerosis in the COVID-19 era." Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology vol. (2022). doi: https://doi.org/10.1007/s10072-022-05868-5
Toscano S, Patti F, Chisari CG, Arena S, Finocchiaro C, Schillaci CE, Zappia M. Reliability of televisits for patients with mild relapsing-remitting multiple sclerosis in the COVID-19 era. Neurol Sci. 2022 Jan 11; doi: 10.1007/s10072-022-05868-5. Epub 2022 Jan 11. PMID: 35018548.
Copy Download .nbib Format: NLM
Synergistic Drug Combinations Prevent Resistance in ALK+ Anaplastic Large Cell Lymphoma.

Cancers

Arosio G, Sharma GG, Villa M, Mauri M, Crespiatico I, Fontana D, Manfroni C, Mastini C, Zappa M, Magistroni V, Ceccon M, Redaelli S, Massimino L, Garbin A, Lovisa F, Mussolin L, Piazza R, Gambacorti-Passerini C, Mologni L.
PMID: 34503232
Cancers (Basel). 2021 Sep 01;13(17). doi: 10.3390/cancers13174422.

Anaplastic lymphoma kinase-positive (ALK+) anaplastic large-cell lymphoma (ALCL) is a subtype of non-Hodgkin lymphoma characterized by expression of the oncogenic NPM/ALK fusion protein. When resistant or relapsed to front-line chemotherapy, ALK+ ALCL prognosis is very poor. In these patients,...

Cite
Arosio G, Sharma GG, Villa M, et al. Synergistic Drug Combinations Prevent Resistance in ALK+ Anaplastic Large Cell Lymphoma. Cancers (Basel). 2021;13(17)doi: 10.3390/cancers13174422.
Arosio, G., Sharma, G. G., Villa, M., Mauri, M., Crespiatico, I., Fontana, D., Manfroni, C., Mastini, C., Zappa, M., Magistroni, V., Ceccon, M., Redaelli, S., Massimino, L., Garbin, A., Lovisa, F., Mussolin, L., Piazza, R., Gambacorti-Passerini, C., & Mologni, L. (2021). Synergistic Drug Combinations Prevent Resistance in ALK+ Anaplastic Large Cell Lymphoma. Cancers, 13(17), . https://doi.org/10.3390/cancers13174422
Arosio, Giulia, et al. "Synergistic Drug Combinations Prevent Resistance in ALK+ Anaplastic Large Cell Lymphoma." Cancers vol. 13,17 (2021). doi: https://doi.org/10.3390/cancers13174422
Arosio G, Sharma GG, Villa M, Mauri M, Crespiatico I, Fontana D, Manfroni C, Mastini C, Zappa M, Magistroni V, Ceccon M, Redaelli S, Massimino L, Garbin A, Lovisa F, Mussolin L, Piazza R, Gambacorti-Passerini C, Mologni L. Synergistic Drug Combinations Prevent Resistance in ALK+ Anaplastic Large Cell Lymphoma. Cancers (Basel). 2021 Sep 01;13(17). doi: 10.3390/cancers13174422. PMID: 34503232; PMCID: PMC8431561.
Copy Download .nbib Format: NLM
Impact of short stature on quality of life: A systematic literature review.

Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society

Backeljauw P, Cappa M, Kiess W, Law L, Cookson C, Sert C, Whalen J, Dattani MT.
PMID: 33975197
Growth Horm IGF Res. 2021 Apr-Jun;57:101392. doi: 10.1016/j.ghir.2021.101392. Epub 2021 Apr 30.

OBJECTIVE: We sought to obtain a better understanding of the burden of short stature using a systematic literature review.METHODS: Studies of the burden of short stature, of any cause in adults and children, were searched using Embase, MEDLINE and...

Cite
Backeljauw P, Cappa M, Kiess W, et al. Impact of short stature on quality of life: A systematic literature review. Growth Horm IGF Res. 2021;57:101392doi: 10.1016/j.ghir.2021.101392.
Backeljauw, P., Cappa, M., Kiess, W., Law, L., Cookson, C., Sert, C., Whalen, J., & Dattani, M. T. (2021). Impact of short stature on quality of life: A systematic literature review. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society, 57101392. https://doi.org/10.1016/j.ghir.2021.101392
Backeljauw, Philippe, et al. "Impact of short stature on quality of life: A systematic literature review." Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society vol. 57 (2021): 101392. doi: https://doi.org/10.1016/j.ghir.2021.101392
Backeljauw P, Cappa M, Kiess W, Law L, Cookson C, Sert C, Whalen J, Dattani MT. Impact of short stature on quality of life: A systematic literature review. Growth Horm IGF Res. 2021 Apr-Jun;57:101392. doi: 10.1016/j.ghir.2021.101392. Epub 2021 Apr 30. PMID: 33975197.
Copy Download .nbib Format: NLM
Growth in Children With Noonan Syndrome and Effects of Growth Hormone Treatment on Adult Height.

Frontiers in endocrinology

Libraro A, D'Ascanio V, Cappa M, Chiarito M, Digilio MC, Einaudi S, Grandone A, Maghnie M, Mazzanti L, Mussa A, Patti G, Scarano E, Spinuzza A, Vannelli S, Wasniewska MG, Ferrero GB, Faienza MF.
PMID: 35002956
Front Endocrinol (Lausanne). 2021 Dec 22;12:761171. doi: 10.3389/fendo.2021.761171. eCollection 2021.

OBJECTIVES: Growth impairment is a common manifestation in Noonan syndrome (NS). Recombinant human GH (rhGH) treatment has been shown to increase growth and adult height (AH) in a few studies. We aimed to evaluate the growth trajectory towards the...

Cite
Libraro A, D'Ascanio V, Cappa M, et al. Growth in Children With Noonan Syndrome and Effects of Growth Hormone Treatment on Adult Height. Front Endocrinol (Lausanne). 2021;12:761171doi: 10.3389/fendo.2021.761171.
Libraro, A., D'Ascanio, V., Cappa, M., Chiarito, M., Digilio, M. C., Einaudi, S., Grandone, A., Maghnie, M., Mazzanti, L., Mussa, A., Patti, G., Scarano, E., Spinuzza, A., Vannelli, S., Wasniewska, M. G., Ferrero, G. B., & Faienza, M. F. (2021). Growth in Children With Noonan Syndrome and Effects of Growth Hormone Treatment on Adult Height. Frontiers in endocrinology, 12761171. https://doi.org/10.3389/fendo.2021.761171
Libraro, Annachiara, et al. "Growth in Children With Noonan Syndrome and Effects of Growth Hormone Treatment on Adult Height." Frontiers in endocrinology vol. 12 (2021): 761171. doi: https://doi.org/10.3389/fendo.2021.761171
Libraro A, D'Ascanio V, Cappa M, Chiarito M, Digilio MC, Einaudi S, Grandone A, Maghnie M, Mazzanti L, Mussa A, Patti G, Scarano E, Spinuzza A, Vannelli S, Wasniewska MG, Ferrero GB, Faienza MF. Growth in Children With Noonan Syndrome and Effects of Growth Hormone Treatment on Adult Height. Front Endocrinol (Lausanne). 2021 Dec 22;12:761171. doi: 10.3389/fendo.2021.761171. eCollection 2021. PMID: 35002956; PMCID: PMC8730290.
Copy Download .nbib Format: NLM
Showing 385 to 388 of 388 entries